Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Cell-based reference samples designed with specific differences in microRNA biomarkers.

Pine PS, Lund SP, Stass SA, Kukuruga D, Jiang F, Sorbara L, Srivastava S, Salit M.

BMC Biotechnol. 2018 Mar 20;18(1):17. doi: 10.1186/s12896-018-0423-4.

2.

Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.

Pine PS, Lund SP, Parsons JR, Vang LK, Mahabal AA, Cinquini L, Kelly SC, Kincaid H, Crichton DJ, Spira A, Liu G, Gower AC, Pass HI, Goparaju C, Dubinett SM, Krysan K, Stass SA, Kukuruga D, Van Keuren-Jensen K, Courtright-Lim A, Thompson KL, Rosenzweig BA, Sorbara L, Srivastava S, Salit ML.

BMC Genomics. 2018 Mar 6;19(1):180. doi: 10.1186/s12864-018-4496-1.

3.

A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.

Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Jack Lee J, Srivastava S, Sen S, McNeill Killary A.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw341.

4.

Analysis of Lung Flute-collected Sputum for Lung Cancer Diagnosis.

Su J, Anjuman N, Guarnera MA, Zhang H, Stass SA, Jiang F.

Biomark Insights. 2015 Aug 4;10:55-61. doi: 10.4137/BMI.S26883. eCollection 2015.

5.

Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis.

Su J, Liao J, Gao L, Shen J, Guarnera MA, Zhan M, Fang H, Stass SA, Jiang F.

Oncotarget. 2016 Feb 2;7(5):5131-42. doi: 10.18632/oncotarget.4219.

6.

Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer.

Ma J, Lin Y, Zhan M, Mann DL, Stass SA, Jiang F.

Lab Invest. 2015 Oct;95(10):1197-206. doi: 10.1038/labinvest.2015.88. Epub 2015 Jul 6.

7.

Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules.

Xing L, Su J, Guarnera MA, Zhang H, Cai L, Zhou R, Stass SA, Jiang F.

Clin Cancer Res. 2015 Jan 15;21(2):484-9. doi: 10.1158/1078-0432.CCR-14-1873.

8.

Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep sequencing.

Gao L, Ma J, Mannoor K, Guarnera MA, Shetty A, Zhan M, Xing L, Stass SA, Jiang F.

Int J Cancer. 2015 Mar 15;136(6):E623-9. doi: 10.1002/ijc.29169. Epub 2014 Sep 4.

9.

Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing.

Ma J, Mannoor K, Gao L, Tan A, Guarnera MA, Zhan M, Shetty A, Stass SA, Xing L, Jiang F.

Mol Oncol. 2014 Oct;8(7):1208-19. doi: 10.1016/j.molonc.2014.03.019. Epub 2014 Apr 15.

10.

Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis.

Shen J, Liao J, Guarnera MA, Fang H, Cai L, Stass SA, Jiang F.

J Thorac Oncol. 2014 Jan;9(1):33-40. doi: 10.1097/JTO.0000000000000025.

11.

Evaluation of lung flute in sputum samples for molecular analysis of lung cancer.

Anjuman N, Li N, Guarnera M, Stass SA, Jiang F.

Clin Transl Med. 2013 Sep 22;2(1):15. doi: 10.1186/2001-1326-2-15.

12.

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.

Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, Pereira NL, Roden DM, Johnson JA, Klein TE; Pharmacogenomics Research Network Translational Pharmacogenetics Program Group, Shuldiner AR, Vesely M, Robinson SW, Ambulos N Jr, Stass SA, Kelemen MD, Brown LA, Pollin TI, Beitelshees AL, Zhao RY, Pakyz RE, Palmer K, Alestock T, O'Neill C, Maloney K, Branham A, Sewell D, Relling MV, Crews K, Hoffman J, Cross S, Haidar C, Baker D, Hicks JK, Bell G, Greeson F, Gaur A, Reiss U, Huettel A, Cheng C, Gajjar A, Pappo A, Howard S, Hudson M, Pui CH, Jeha S, Evans WE, Broeckel U, Altman RB, Gong L, Whirl-Carrillo M, Klein TE, Sadee W, Manickam K, Sweet KM, Embi PJ, Roden D, Peterson J, Denny J, Schildcrout J, Bowton E, Pulley J, Beller M, Mitchell J, Danciu I, Price L, Pereira NL, Weinshilboum R, Wang L, Johnson JA, Nelson D, Clare-Salzler M, Elsey A, Burkley B, Langaee T, Liu F, Nessl D, Dong HJ, Lesko L, Freimuth RR, Chute CG.

Clin Pharmacol Ther. 2013 Aug;94(2):207-10. doi: 10.1038/clpt.2013.59. Epub 2013 Mar 19. No abstract available.

13.

Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer.

Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, Xue L, Liu Y, Yan X, Shen J, Mannoor K, Deepak J, Donahue JM, Stass SA, Xing L, Jiang F.

Oncogene. 2014 Feb 27;33(9):1181-9. doi: 10.1038/onc.2013.42. Epub 2013 Mar 11.

14.

Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive HIV+/EBV+ diffuse large B-cell lymphomas.

Zhao XF, Zhao MY, Chai L, Kukuruga D, Tan M, Stass SA.

Int J Clin Exp Pathol. 2013;6(2):148-54. Epub 2013 Jan 15.

15.

MicroRNAs as potential biomarkers in human solid tumors.

Shen J, Stass SA, Jiang F.

Cancer Lett. 2013 Feb 28;329(2):125-36. doi: 10.1016/j.canlet.2012.11.001. Epub 2012 Nov 27. Review.

16.

Pathogenesis of early leukemia and lymphoma.

Zhao XF, Reitz M, Chen QC, Stass S.

Cancer Biomark. 2010;9(1-6):341-74. doi: 10.3233/CBM-2011-0178. Review.

PMID:
22112484
17.

A panel of sputum-based genomic marker for early detection of lung cancer.

Jiang F, Todd NW, Li R, Zhang H, Fang H, Stass SA.

Cancer Prev Res (Phila). 2010 Dec;3(12):1571-8. doi: 10.1158/1940-6207.CAPR-10-0128. Epub 2010 Sep 23.

18.

Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas.

Paun BC, Kukuruga D, Jin Z, Mori Y, Cheng Y, Duncan M, Stass SA, Montgomery E, Hutcheon D, Meltzer SJ.

Cancer. 2010 Oct 1;116(19):4495-501. doi: 10.1002/cncr.25348.

19.

Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer.

Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, Stass SA, Jiang F.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):327-37. doi: 10.1158/1055-9965.EPI-09-0865.

20.

ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome.

Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, Stass SA, Jiang F.

Lab Invest. 2010 Feb;90(2):234-44. doi: 10.1038/labinvest.2009.127. Epub 2009 Dec 14.

21.

Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer.

Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA, Jiang F.

Lung Cancer. 2010 Feb;67(2):170-6. doi: 10.1016/j.lungcan.2009.04.004. Epub 2009 May 14.

22.

Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.

Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, Katz RL.

Mol Cancer Res. 2009 Mar;7(3):330-8. doi: 10.1158/1541-7786.MCR-08-0393. Epub 2009 Mar 10.

23.

Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.

Zhao MY, Auerbach A, D'Costa AM, Rapoport AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera N, Zhao XF.

Clin Cancer Res. 2009 Mar 1;15(5):1708-20. doi: 10.1158/1078-0432.CCR-08-1543. Epub 2009 Feb 17.

24.

Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer.

Jiang F, Todd NW, Qiu Q, Liu Z, Katz RL, Stass SA.

Lung Cancer. 2009 Oct;66(1):58-63. doi: 10.1016/j.lungcan.2009.01.004. Epub 2009 Jan 31.

25.

Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.

Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE.

J Proteome Res. 2009 Jan;8(1):113-7. doi: 10.1021/pr800545q.

26.

C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology.

Zhao XF, Hassan A, Perry A, Ning Y, Stass SA, Dehner LP.

Int J Clin Exp Pathol. 2008 Jan 1;1(1):65-74.

27.

Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis.

Qiu Q, Todd NW, Li R, Peng H, Liu Z, Yfantis HG, Katz RL, Stass SA, Jiang F.

Cancer. 2008 Aug 25;114(4):275-83. doi: 10.1002/cncr.23596.

28.

Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality.

Sasai K, Parant JM, Brandt ME, Carter J, Adams HP, Stass SA, Killary AM, Katayama H, Sen S.

Oncogene. 2008 Jul 3;27(29):4122-7. doi: 10.1038/onc.2008.47. Epub 2008 Mar 17.

PMID:
18345035
29.

Detecting genomic aberrations by fluorescence in situ hybridization with quantum dots-labeled probes.

Jiang Z, Li R, Todd NW, Stass SA, Jiang F.

J Nanosci Nanotechnol. 2007 Dec;7(12):4254-9.

PMID:
18283800
30.

Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study.

Alexiev BA, Wang W, Ning Y, Chumsri S, Gojo I, Rodgers WH, Stass SA, Zhao XF.

Diagn Pathol. 2007 Oct 31;2:42.

31.

Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target.

Fan T, Li R, Todd NW, Qiu Q, Fang HB, Wang H, Shen J, Zhao RY, Caraway NP, Katz RL, Stass SA, Jiang F.

Cancer Res. 2007 Aug 15;67(16):7901-6.

32.

Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer.

Li R, Todd NW, Qiu Q, Fan T, Zhao RY, Rodgers WH, Fang HB, Katz RL, Stass SA, Jiang F.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):482-7.

33.

Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach.

Li R, Wang H, Bekele BN, Yin Z, Caraway NP, Katz RL, Stass SA, Jiang F.

Oncogene. 2006 Apr 27;25(18):2628-35.

PMID:
16369491
34.

Prediction of survival in patients with esophageal carcinoma using artificial neural networks.

Sato F, Shimada Y, Selaru FM, Shibata D, Maeda M, Watanabe G, Mori Y, Stass SA, Imamura M, Meltzer SJ.

Cancer. 2005 Apr 15;103(8):1596-605. Review.

35.

An unsupervised approach to identify molecular phenotypic components influencing breast cancer features.

Selaru FM, Yin J, Olaru A, Mori Y, Xu Y, Epstein SH, Sato F, Deacu E, Wang S, Sterian A, Fulton A, Abraham JM, Shibata D, Baquet C, Stass SA, Meltzer SJ.

Cancer Res. 2004 Mar 1;64(5):1584-8.

36.

Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2.

Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ.

Cancer Res. 2002 Oct 1;62(19):5463-9.

37.

Branched co-polymers of histidine and lysine are efficient carriers of plasmids.

Chen QR, Zhang L, Stass SA, Mixson AJ.

Nucleic Acids Res. 2001 Mar 15;29(6):1334-40.

38.

Co-polymer of histidine and lysine markedly enhances transfection efficiency of liposomes.

Chen QR, Zhang L, Stass SA, Mixson AJ.

Gene Ther. 2000 Oct;7(19):1698-705.

39.

Molecular pathology: role in improving patient outcome: Overview.

Stass SA, Grody WW.

Arch Pathol Lab Med. 1999 Nov;123(11):1000-1. No abstract available.

PMID:
10539895
40.

Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy.

Berlyn KA, Ponniah S, Stass SA, Malone JG, Hamlin-Green G, Lim JK, Cottler-Fox M, Tricot G, Alexander RB, Mann DL, Malone RW.

J Biotechnol. 1999 Aug 20;73(2-3):155-79. Review.

PMID:
10486925
41.

Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice.

Chen QR, Kumar D, Stass SA, Mixson AJ.

Cancer Res. 1999 Jul 15;59(14):3308-12.

42.

Recommended policies for uses of human tissue in research, education, and quality control. Ad Hoc Committee on Stored Tissue, College of American Pathologists.

Grizzle W, Grody WW, Noll WW, Sobel ME, Stass SA, Trainer T, Travers H, Weedn V, Woodruff K.

Arch Pathol Lab Med. 1999 Apr;123(4):296-300.

PMID:
10320140
43.

Oncogenes and tumor suppressor genes: therapeutic implications.

Stass SA, Mixson J.

Clin Cancer Res. 1997 Dec;3(12 Pt 2):2687-95. Review.

44.

A geometric study of the amino acid sequence of class I HLA molecules.

Cano P, Fan B, Stass S.

Immunogenetics. 1998 Oct;48(5):324-34.

PMID:
9745009
45.

In vivo gene therapy with a cationic polymer markedly enhances the antitumor activity of antiangiogenic genes.

Xu M, Chen QR, Kumar D, Stass SA, Mixson AJ.

Mol Genet Metab. 1998 Jul;64(3):193-7.

PMID:
9719628
46.

Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo.

Xu M, Kumar D, Stass SA, Mixson AJ.

Mol Genet Metab. 1998 Feb;63(2):103-9.

PMID:
9562963
47.

Histologically discordant lymphomas with B-cell and T-cell components.

Abruzzo LV, Griffith LM, Nandedkar M, Aguilera NS, Taubenberger JK, Raffeld M, Stass SA, Abbondanzo SL, Jaffe ES.

Am J Clin Pathol. 1997 Sep;108(3):316-23.

PMID:
9291461
48.

Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic gammadelta T cell lymphoma.

Alonsozana EL, Stamberg J, Kumar D, Jaffe ES, Medeiros LJ, Frantz C, Schiffer CA, O'Connell BA, Kerman S, Stass SA, Abruzzo LV.

Leukemia. 1997 Aug;11(8):1367-72.

PMID:
9264394
49.

Downregulation of RAR alpha in mice by antisense transgene leads to a compensatory increase in RAR beta and RAR gamma and development of lymphoma.

Manshouri T, Yang Y, Lin H, Stass SA, Glassman AB, Keating MJ, Albitar M.

Blood. 1997 Apr 1;89(7):2507-15.

50.

Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity.

Xu M, Kumar D, Srinivas S, Detolla LJ, Yu SF, Stass SA, Mixson AJ.

Hum Gene Ther. 1997 Jan 20;8(2):177-85.

PMID:
9017421

Supplemental Content

Support Center